More diverse investigators could help diversify clinical trials Updated on: April 18,2025 More diverse investigators could help diversify clinical trials Updated on:April 18,2025
Combination approach could overcome treatment resistance in deadly breast cancer Updated on: July 08,2025 Combination approach could overcome treatment resistance in deadly breast cancer Updated on:July 08,2025
Childhood exposure to bacterial toxin may be triggering colorectal cancer among the young, scientists report Updated on: May 18,2025 Childhood exposure to bacterial toxin may be triggering colorectal cancer among the young, scientists report Updated on:May 18,2025
Scientists identify new strategy to fight cancer caused by Epstein-Barr virus Updated on: April 20,2025 Scientists identify new strategy to fight cancer caused by Epstein-Barr virus Updated on:April 20,2025
Depression remission endures five years after psilocybin trial Updated on: September 30,2025 Depression remission endures five years after psilocybin trial Updated on:September 30,2025
New test helps doctors predict a dangerous side effect of cancer treatment Updated on: April 20,2025 New test helps doctors predict a dangerous side effect of cancer treatment Updated on:April 20,2025
Recommendations developed for young adult cancer survivor follow-up care Updated on: October 06,2025 Recommendations developed for young adult cancer survivor follow-up care Updated on:October 06,2025
Novel cell therapy shows promising results in advanced tumor diseases Updated on: May 21,2025 Novel cell therapy shows promising results in advanced tumor diseases Updated on:May 21,2025
Misconceptions keep some cancer patient populations from benefiting from hormone therapy, survey reveals Updated on: October 02,2025 Misconceptions keep some cancer patient populations from benefiting from hormone therapy, survey reveals Updated on:October 02,2025
Subcutaneous amivantamab every 4 weeks plus lazertinib shows high response rate in EGFR-mutated NSCLC Updated on: October 03,2025 Subcutaneous amivantamab every 4 weeks plus lazertinib shows high response rate in EGFR-mutated NSCLC Updated on:October 03,2025